CMAJ has been made aware of errors that occurred in the C-CHANGE guideline published in the Nov. 7, 2022, issue.1
In the “People with obesity, diabetes or hypertension” section on page E1467, glucagon-like peptide-1 (GLP1)-receptor antagonists were listed as therapy to aid with weight loss. This should have read “glucagon-like peptide-1 (GLP1)-receptor agonists.”
In the “Affiliations” section on page E1480, a person who is not an author was inadvertently listed. The following entry has now been removed: “Office of Nutrition Policy Promotion (Aziz), Health Canada, Ottawa, Ont.”
This has been corrected at cmaj.ca.